UCB is A global biopharmaceutical leader committed to improving the lives of people living with severe diseases, highlighted its decade of growth and strategic priorities at the 43rd J.P. Morgan Healthcare Conference in San Francisco. For nearly a century, It has remained steadfast in its dedication to patient-centered innovation, and this commitment has driven its remarkable growth in the fields of immunology and neurology. Now, the company is setting its sights on continued success and transformation, fueled by its unique Patient Value Strategy.
A Legacy of Excellence and Innovation
Over the last ten years, It has solidified its position as a leading player in biopharmaceuticals by prioritizing the needs of patients. Its Patient Value Strategy—a core philosophy that places the well-being and experiences of patients at the center of its efforts—has guided the development of groundbreaking medicines and transformative solutions. This approach has not only established Itself as a pioneer in its field but has also set the stage for sustained growth in the years to come.
“At It, we are looking ahead with confidence and determination,” said Jean-Christophe Tellier, CEO of UCB. “We will continue to deliver differentiated innovation, transforming what is possible for patients, caregivers, medical professionals, and shareholders. Guided by our Patient Value Strategy, we are committed to delivering solutions that truly make a difference, while ensuring a sustainable and inclusive future for all.”
Key Milestones and Achievements
During the presentation at the J.P. Morgan Healthcare Conference, It shared several notable milestones and advancements that underscore its commitment to driving value for patients and stakeholders alike:
- BIMZELX® (bimekizumab): Enhanced Accessibility UCB’s blockbuster immunology drug BIMZELX®, which targets IL-17A and IL-17F, has achieved significantly improved insurance coverage in the United States. This development ensures that more patients can access and afford this transformative treatment. Currently, BIMZELX® is available to patients in 48 countries, reflecting its global impact in addressing conditions like psoriasis, psoriatic arthritis, and axial spondyloarthritis.
- RYSTIGGO® (rozanolixizumab) and ZILBRYSQ® (zilucoplan): Leadership in Generalized Myasthenia Gravis (gMG) It is the first and only company to offer a differentiated portfolio of treatments for generalized myasthenia gravis (gMG). These therapies have received market authorization in more than 20 countries, providing a lifeline to patients struggling with this chronic and debilitating neuromuscular disorder. The availability of both RYSTIGGO® and ZILBRYSQ® demonstrates UCB’s leadership in addressing unmet medical needs in neurology.
- R&D Leadership and Productivity UCB’s robust research and development pipeline has driven industry-leading productivity. Over the past two years, the company has achieved multiple positive Phase 3 trial results, culminating in 25 regulatory approvals and product launches across major regions, including the United States, the European Union, and Japan. These achievements highlight UCB’s commitment to advancing science and delivering innovative therapies to patients worldwide.
- Sustainability Excellence UCB is one of the few biopharmaceutical companies with validated net-zero targets by the Science Based Targets initiative (SBTi). This recognition underscores the company’s dedication to environmental sustainability and societal well-being. UCB’s comprehensive approach to sustainability not only addresses environmental challenges but also fosters inclusivity and equity across its operations.
- Financial Growth and Resilience UCB’s financial performance continues to reflect its strategic focus and operational excellence. As of its November 2024 guidance update, the company expects to achieve revenue near €6 billion for the year, with an adjusted EBITDA margin in the upper range of 23.0-24.5%. Full-year financial results for 2024 will be announced on February 27, 2025. These figures underscore UCB’s resilience and ability to deliver value to its stakeholders.
A Vision for Sustained Growth
Looking to the future, UCB is confident in its ability to sustain growth by leveraging its innovative medicines and patient-centric approach. The company remains dedicated to transforming the lives of patients, caregivers, and healthcare professionals through groundbreaking solutions that address complex medical challenges.
At the heart of UCB’s strategy is a commitment to creating a sustainable and inclusive future. By integrating environmental, social, and governance (ESG) principles into its operations, UCB is ensuring that its growth benefits not only its shareholders but also society as a whole.
Enhancing Access and Affordability
UCB’s efforts to enhance access and affordability for patients reflect its unwavering commitment to equity in healthcare. The company’s focus on securing broad insurance coverage for its therapies, such as BIMZELX®, ensures that more patients can benefit from its innovative treatments. Additionally, UCB’s partnerships with healthcare providers and payers aim to reduce barriers to care and improve health outcomes for underserved populations.
Driving Innovation Through Collaboration
Collaboration is a cornerstone of UCB’s success. By partnering with academic institutions, healthcare organizations, and other stakeholders, It is advancing scientific discovery and accelerating the development of new therapies. These collaborations enable UCB to stay at the forefront of medical innovation and address emerging health challenges effectively.
Commitment to Patients and Communities
UCB’s dedication to improving patient outcomes extends beyond its therapies. The company actively engages with patient communities to understand their needs and priorities. This patient-centric approach informs every aspect of UCB’s operations, from research and development to commercial strategies.
Furthermore, UCB’s commitment to sustainability and social responsibility ensures that its impact extends beyond healthcare. By addressing global challenges such as climate change and inequality, UCB is contributing to a better future for all.
Read more: UCB Highlights a Decade of Growth and Patient-Centered Innovation Strategy
